Feasibility of a Multi-omics Platform for Hematological Malignancies
Recruiting
N/A
Interventional Study
Myeloma Multiple
Chronic Leukemia
Acute Leukemia
Myeloproliferative Disorders
Lymphoproliferative Disorders
Myelodysplastic Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 2 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 1,040 (estimated)
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a biological study based on a collaborative effort involving several Italian haematology centres (including the coordinating centre). The study will be conducted retrospectively and prospectively using bone marrow (BM) or peripheral blood (PB) samples, lymph node or tissue biopsies with metastatic involvement, and other biological fluids, such as cerebrospinal fluid and pathological pleura…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patient aged \> 2 year old
* Retrospective study:
* Patients previously diagnosed with hematological malignancies
* Prospective study:
* Patients with clinical suspect of hematological malignancies requiring a diagnostic assessment using BM or PB samples, biopsies of lymph nod…
Contacts